May 10, 2022

Cytiva opening new facility in Switzerland

By Cytiva Communications
  • New site will house Center of Excellence for cell and gene therapies
  • Products manufactured at site will be used in regulatory approved therapies and clinical trials
  • Building is powered by 100% renewable energy

May 10, 2022

Global life sciences leader Cytiva is opening a new 7 400m² manufacturing facility in Grens, Switzerland on May 31, 2022. The site will manufacture single use kits for the Sepax and Sefia cell processing systems, as well as consumables for Xuri cell expansion systems. It will also serve as a ‘Center of Excellence’ for Cytiva’s Cell and Gene Therapy business and will be a base for European customer training programs.

The site will be home to 250 associates. An opening ceremony will be held on May 31 followed by a LinkedIn Live Broadcast on June 2.

Catarina Flyborg, Vice President, Cell and Gene Therapy, Cytiva says: “Cell and gene therapies have the potential to change the global healthcare landscape. Our new facility in Grens will enable us to meet global demand for our products, while working with our customers to meet their immediate training and development needs. This facility brings us another step closer to our vision where access to life-changing therapies transforms human health.”

Philippe Leuba, Minister of Economic Affairs, Innovation and Sport, State of Vaud, Switzerland, says: “Cytiva is one of the world’s leading life sciences companies. Its decision to expand operations in Switzerland is a testament to our innovation ecosystem that has played a significant role in developing some of the most advanced therapeutics.”

The existing site in Eysins will continue operations through 2023, while full production transfers to the new site in Grens.

Inside the facility

The facility will quadruple Cytiva’s capacity for manufacturing Sefia, Sepax, and Xuri consumable products with two new ISO class 7 cleanrooms, ensuring that increased future demand can be met. The design of the facility adopts GMP principles from raw materials entering the building, through the manufacturing process, to the shipment of finished products.

Cytiva continues to integrate sustainability into its operations. The new site has been built to Swiss Minergie standards, a sustainable building standard recognized globally for its effectiveness in achieving lower energy and resource consumption. Building to this standard provides high-grade, air-tight building envelopes and the continuous renewal of air in the building using an energy-efficient ventilation system. The building is powered by 100% renewable electricity and has roof mounted solar panels. It also has five distinct HVAC systems that optimize environmental conditions in each functional area. Cytiva is investigating the use of ‘dynamic’ cleanroom controls which would further reduce power usage by up to 60%.

R&D facility

A R&D facility is located on the first floor, which consists of several laboratories designed for multidisciplinary engineering and cell biology processing capabilities. The customer training center, located on the second floor, is a fully equipped 100m² BSL2 laboratory that will enable process and application training with Cytiva instruments, consumables, and software. Cytiva associates will also be able to use this facility to develop knowledge and skills on current and future products and processes.

Applications open

Recruitment is ongoing in Grens to hire manufacturing staff, management, as well as warehouse operators, material handlers, and R&D scientists. Go here to see all the available roles.

About Cytiva

Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.

Media Contact:

[email protected]
+1 774 245 3893